<SEC-DOCUMENT>0001005286-25-000029.txt : 20250117
<SEC-HEADER>0001005286-25-000029.hdr.sgml : 20250117
<ACCEPTANCE-DATETIME>20250117172727
ACCESSION NUMBER:		0001005286-25-000029
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250117
DATE AS OF CHANGE:		20250117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIFECORE BIOMEDICAL, INC. \DE\
		CENTRAL INDEX KEY:			0001005286
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943025618
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0525

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27446
		FILM NUMBER:		25539675

	BUSINESS ADDRESS:	
		STREET 1:		3515 LYMAN BOULEVARD
		CITY:			CHASKA
		STATE:			MN
		ZIP:			55318
		BUSINESS PHONE:		9523684300

	MAIL ADDRESS:	
		STREET 1:		3515 LYMAN BOULEVARD
		CITY:			CHASKA
		STATE:			MN
		ZIP:			55318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LANDEC CORP \CA\
		DATE OF NAME CHANGE:	19951222
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>a2025-01x17form8xkspecialm.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id55a01a586cf4c449d1fb5f322d7dd2e_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM 8-K</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 17, 2025</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:112%">LIFECORE BIOMEDICAL, INC.</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="margin-bottom:10pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">000-27446</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94-3025618</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission file number)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</font></td></tr></table></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:23.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3515 Lyman Boulevard</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Chaska,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Minnesota</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55318</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</font></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(952) 368-4300</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</font></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;&#8195;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;&#8195;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;&#8195;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;&#8195;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="margin-bottom:10pt;padding-right:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div style="margin-bottom:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LFCR</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The NASDAQ Global Select Market</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#8195;&#9744;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#8195;&#9744;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div><div id="id55a01a586cf4c449d1fb5f322d7dd2e_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 Other Event.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2025, Lifecore Biomedical, Inc. (&#8220;Lifecore&#8221; or the &#8220;Company&#8221;) issued a press release announcing that it intends to hold a special meeting of its stockholders (the &#8220;Special Meeting&#8221;) on April 10, 2025 to consider and vote on a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of its common stock, par value $0.001 per share (&#8220;Common Stock&#8221;) issuable upon conversion of shares of the Company&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Convertible Preferred Stock&#8221;) in an amount in excess of 19.99% of the number of shares of the Common Stock outstanding immediately prior to the issuance of such Convertible Preferred Stock (the &#8220;Proposal&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or the Company&#8217;s future performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, the Company&#8217;s plans and expectations regarding the proposed Special Meeting and the Proposal, and the Company&#8217;s intention with respect to future capital raising activities. These forward-looking statements are not guarantees of future performance, and all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, the ability for the Company to hold the Special Meeting on the anticipated timeline, if at all, changes in the Company&#8217;s liquidity needs, as well as the other risks set forth in the Company&#8217;s filings with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended May 26, 2024, and the Company&#8217;s Quarterly Reports on Form 10-Q for the fiscal quarters ended August 25, 2024, and November 24, 2024. The forward-looking statements contained herein speak only as of the date of this release. the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement contained herein to reflect any change in the Company&#8217;s expectations or any change in events, conditions or circumstances on which any such statement is based.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information and Where to Find It</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Special Meeting, Lifecore intends to file proxy materials with the SEC, including a preliminary proxy statement and a definitive proxy statement. THIS DOCUMENT IS NOT A SUBSTITUTE FOR THE PROXY STATEMENT OR ANY OTHER DOCUMENT THAT LIFECORE MAY FILE WITH THE SEC. THE DEFINITIVE PROXY STATEMENT (IF AND WHEN AVAILABLE) WILL BE MAILED TO STOCKHOLDERS OF LIFECORE. Stockholders of Lifecore and other interested persons are urged to read all relevant documents filed with the SEC when they become available, including the preliminary and definitive proxy statements to be filed in connection with the Special Meeting, because they will contain important information about the Special Meeting and the Proposal. Stockholders will be able to obtain such documents (if and when available) free of charge at the SEC&#8217;s website at www.sec.gov, or free of charge from the Company by directing a request to Lifecore Biomedical, Inc., Attn&#58; Secretary, 3515 Lyman Boulevard, Chaska, MN 55318 (telephone number&#58; 952-368-4300).</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participants in the Solicitation</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore and its directors, executive officers and other members of management and employees may be deemed, under SEC rules, to be &#8220;participants&#8221; in the solicitation of proxies from stockholders of the Company with respect to the proposals to be submitted to the Company&#8217;s stockholders at the Special Meeting. Information about the Company&#8217;s directors and executive officers is set forth in the Company&#8217;s Definitive Proxy Statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on September 23, 2024. To the extent holdings of the Company&#8217;s securities by its directors or executive officers have changed from the amounts set forth in such Definitive Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the direct or indirect interests, by security holdings or otherwise, of the participants in the solicitation, which may, in some cases, be different than those of the Company&#8217;s stockholders generally, will be set forth in the preliminary and definitive proxy statements to be filed in connection with the Special Meeting.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are furnished as part of this report&#58;</font></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a2025-01x17form8xkex991.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a2025-01x17form8xkex991.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Press Release issued January 17, 2025 by Lifecore Biomedical, Inc.</a></font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div><div id="id55a01a586cf4c449d1fb5f322d7dd2e_10"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURE</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; January 17, 2025</font></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIFECORE BIOMEDICAL, INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ryan D. Lake</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryan D. Lake</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2025-01x17form8xkex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5139f633c98e43ccb2c1cd9558e8fc5c_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:10pt;text-align:justify"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"></div><div style="margin-bottom:14pt;padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Lifecore Biomedical Announces Special Stockholder Meeting</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHASKA, Minn., January 17, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -- Lifecore Biomedical, Inc. (NASDAQ&#58; LFCR) (&#8220;Lifecore&#8221;), a fully integrated contract development and manufacturing organization (&#8220;CDMO&#8221;), today announced that it intends to hold a special meeting of its stockholders (the &#8220;Special Meeting&#8221;) on April 10, 2025 (the &#8220;Special Meeting Date&#8221;), to consider and vote on a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of its common stock, par value $0.001 per share (&#8220;Common Stock&#8221;) issuable upon conversion of shares of Lifecore&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Convertible Preferred Stock&#8221;) in an amount in excess of 19.99% of the number of shares of the Common Stock outstanding immediately prior to the issuance of such Convertible Preferred Stock (the &#8220;Proposal&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Convertible Preferred Stock, the holders currently have the right to convert their shares of Convertible Preferred Stock into Common Stock, subject to certain limitations. Such limitations include limiting the ability to convert in an amount in excess of 19.99% of the number of shares of the Common Stock outstanding immediately prior to the issuance of such Convertible Preferred Stock (the &#8220;Convertible Preferred Stock Exchange Cap&#8221;). As contemplated by the Convertible Preferred Stock Securities Purchase Agreement dated January 9, 2023 (the &#8220;Purchase Agreement&#8221;), Lifecore is seeking stockholder approval for the Proposal, thereby eliminating the Convertible Preferred Stock Exchange Cap. Based on the current conversion price of the Convertible Preferred Stock, the maximum number of shares of Common Stock that the Convertible Stock can be converted into is 6,056,284 shares. The Proposal, if approved, would allow the potential conversion of Convertible Preferred Stock beyond the current limit in accordance with its terms. As of the date of this press release, no holders of Lifecore&#8217;s Convertible Preferred Stock have elected to convert their shares to Common Stock. This meeting is being held solely for the purpose of accommodating the terms of the Purchase Agreement, and Lifecore currently has no plans to raise additional equity capital.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore&#8217;s board of directors has approved that holders of record of Lifecore&#8217;s Common Stock and Convertible Preferred Stock as of the close of business on February 18, 2025 (the &#8220;Record Date&#8221;), will be entitled to receive notice of and to vote at the Special Meeting. The Special Meeting Date and the Record Date are subject to change.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore plans to file a preliminary proxy statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the Special Meeting. After receiving clearance from the SEC, Lifecore will file a definitive proxy statement with the SEC (the &#8220;Definitive Proxy Statement&#8221;), which will be sent to stockholders. The Definitive Proxy Statement will contain further details regarding the Special Meeting, including the meeting date and how stockholders can participate in and vote at the meeting.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Lifecore Biomedical</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore Biomedical, Inc. (Nasdaq&#58; LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">categories to bring their innovations to market. For more information about Lifecore, visit Lifecore&#8217;s website at www.lifecore.com.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Important Cautions Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or Lifecore&#8217;s future performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, Lifecore&#8217;s plans and expectations regarding the proposed Special Meeting and the Proposal, and Lifecore&#8217;s intention with respect to future capital raising activities. These forward-looking statements are not guarantees of future performance, and all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, the ability for Lifecore to hold the Special Meeting on the anticipated timeline, if at all, changes in Lifecore&#8217;s liquidity needs, as well as the other risks set forth in Lifecore&#8217;s filings with the Securities and Exchange Commission, including Lifecore&#8217;s Annual Report on Form 10-K for the fiscal year ended May 26, 2024, and Lifecore&#8217;s Quarterly Reports on Form 10-Q for the fiscal quarters ended August 25, 2024, and November 24, 2024. The forward-looking statements contained herein speak only as of the date of this release. Lifecore expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement contained herein to reflect any change in Lifecore&#8217;s expectations or any change in events, conditions or circumstances on which any such statement is based.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information and Where to Find It</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Special Meeting, Lifecore intends to file proxy materials with the SEC, including a preliminary proxy statement and a definitive proxy statement. THIS DOCUMENT IS NOT A SUBSTITUTE FOR THE PROXY STATEMENT OR ANY OTHER DOCUMENT THAT LIFECORE MAY FILE WITH THE SEC. THE DEFINITIVE PROXY STATEMENT (IF AND WHEN AVAILABLE) WILL BE MAILED TO STOCKHOLDERS OF LIFECORE. Stockholders of Lifecore and other interested persons are urged to read all relevant documents filed with the SEC when they become available, including the preliminary and definitive proxy statements to be filed in connection with the Special Meeting, because they will contain important information about the Special Meeting and the Proposal. Stockholders will be able to obtain such documents (if and when available) free of charge at the SEC&#8217;s website at www.sec.gov, or free of charge from Lifecore by directing a request to Lifecore Biomedical, Inc., Attn&#58; Secretary, 3515 Lyman Boulevard, Chaska, MN 55318 (telephone number&#58; 952-368-4300).</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participants in the Solicitation</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore and its directors, executive officers and other members of management and employees may be deemed, under SEC rules, to be &#8220;participants&#8221; in the solicitation of proxies from Lifecore&#8217;s stockholders with respect to the proposals to be submitted to Lifecore&#8217;s stockholders at the Special Meeting. Information about Lifecore&#8217;s directors and executive officers is set forth in Lifecore&#8217;s Definitive Proxy Statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on September 23, 2024. To the extent holdings of Lifecore&#8217;s securities by its directors or executive officers have changed from the amounts set forth in such Definitive Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the direct or indirect interests, by security holdings or otherwise, of the participants in the solicitation, which may, in some cases, be different than those of Lifecore&#8217;s stockholders generally, will be set forth in the preliminary and definitive proxy statements to be filed in connection with the Special Meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lifecore Biomedical, Inc. Contact Information&#58;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vida Strategic Partners</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stephanie Diaz (Investors)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">415-675-7401</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sdiaz&#64;vidasp.com</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tim Brons (Media)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">415-675-7402</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tbrons&#64;vidasp.com</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ryan D. Lake (CFO)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore Biomedical</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">952-368-6244</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ryan.lake&#64;lifecore.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@   ^\   &3" 8   !9!2.V    "7!(67,  $SE
M  !,Y0%USO"5  !NL$E$051XVNS7,0T   S#L/(GW;*8=M@0\B4%    7HL$
M    8-X!    \PX   #F'0   ##O    @'D'    \PX   "8=P   ##O
M@'D'    S#L   "8=P   ,"\ P   .8=    S#L   !@W@$  ,"\ P   .8=
M    ,.\   !@W@$   #S#@   .8=    ,.\   " >0<   #S#@   )AW
MP+P#  " >0<   #,.P   )AW    P+P#    YAT N#,   #__^S7,0T   S#
ML/$GW9'H4\F&D"\) %!U$@   (!Y!P   ,P[    F'<   # O ,   #F'0
M ,P[    8-X!  # O ,   #F'0   ##O    8-X!    \PX   "8=P   ##O
M    @'D'    \PX   "8=P   ,"\ P  @'D'    S#L   "8=P   ,"\ P
M .8=    S#L   !@W@$   #S#@   .8=    ,.\   !@W@$   #S#@   )AW
M    ,.^['@  ___LUS$-   ,P[#Q)]VQJ'K8$/(E 0  @&4G 0   )AW
MP+P#  " >0<   #,.P   &#> 0  P+P#    YAT   #,.P   &#> 0   /,.
M    YAT    P[P   (!Y!P   /,.    F'<    P[P   (!Y!P   ,P[
MF'<   # O ,  (!Y!P   ,P[    8-X!  # O ,   #F'0   ##O    8-X!
M    \PX   #F'0   ##O    @'D' "AZ    ___LUS$-   ,P[#Q)]V1Z%/)
MAI O"0 TG00   !@W@$   #S#@   .8=    ,.\   " >0<   #S#@   )AW
M    ,.\   " >0<   #,.P   )AW    P+P#    YAT   #,.P   &#> 0
MP+P#    YAT    P[P   &#> 0   /,.    YAT    P[P   (!Y!P   /,.
M    F'<   # O ,  (!Y!P   ,P[    F'<   # O ,   #F'0   ,P[PQX
M /__[)V)>U15ML7?7T5 0!\J@C-MV]+=MC(H\R"@H#*)#._92JM/!5%H%&T4
MA 0R#T42II )R$@@"9F3&I(:DIJG9+VSSZT(ABA5F0BP?M]W^FND4E67G'N_
MN^[:>VV $$(((8000L@DYK_X3T ((8000@@AA%"\$T(((8000@@AA.*=D(>3
M@0&@7_U/M%^M:+_Z\\ #=7Q1=3AA=6S] _Q=DTE\'L+8IT&U82,#W*^$$$((
MH7@GA P5MTHL!$-1>'QA]'F#"(6C#\RQB0#RA/O1'8C"'Z4:(I.7B-J>5G\4
MK=X(G,&H%O$4\(000@BA>">$_.JX._N"J&_M165]#R[7V6#N\6H!WW\?._#R
MS7U*#5F4&*ITAG#.&D"3.PQOI%^[FH1,)H)*I?<$HBBR!9#1X4=I3U"+>-G#
MDU7 1]2YY M$T.L)H<<54-<-'SJL7K4\:#6[T=C>BX:V6ZM1K9OJOS5W]J'=
MXD&GS0MSMQ<VAQ^.W@#<WA "P:A^7[GV\"PEA!!"*-X)(;???/LC**ZRXE\_
M5&#[_E)LVU>"[*)6=*F;:G\P@OM1Y\IW#D0'<+TWC.,M7NRN<F%]F0/_:?*@
M2@EY1RBJ!1'% ;GG>Q5&6T>[+X)"2P#_K.G%ZA([MEYUXJC:K\T>$?#]]WRO
M#L3.*ZG2B43[]<,]$=UUS4Y<J# C]6PS#J?68=_Q&GQUK!H??7<%FSXOPCN?
MWEJ;/BO"YB^+L>O;<GQ^M!('3M3@\.DZ_)+7J*XY;2BKM6EQW^T,Z(<"498=
M$$(((13OA!#H&V-[;P!5]3WJ)KH6\S?EX.E5:7AF=3KV'"J'J:0=[58/ J'[
MRX&7;^J-#.!F7P3)K3Z\K43[O (K'LLVXZU2.X[<]&@GWA7JU_W%A-Q+Y"%3
M=S"* HL?>VM[\>KY;CR68\;3)@LVJ+V;VNY#0U_XGI;0R^D?CO2CSQO6KOIU
M)=C+:JW(NMB*(VG7L?>'"KS_13&6["K JYOS\/?W<_'"6YF8ON DIKYVXM?U
MR.LG\=@;*9B[,DU?;Q9L,V')S@*LWWL!.PZ4:='_<W8#LB^VH?)&#]SJ\P@A
MA!!"\4[(0XTX[KV>($IK;?CTQPJ\^6$!GEAZ"C,7)^,QM?ZR,1M;OBI&7K$(
M>'=,P$_^XY+O*&7&]4KL_-3LQ:;+#KQPQHI'E7"?EMFE!)$5RXKM^%X)^ I'
M" XEFJ(LSR7W8J_""*=K]XKC[M>.^RMG;7@\UZ+WZHPL,^85V+"NS*X=>'F=
M5Y>33_"U(FJ4QEOL/BVHD_.;\*D2ZR*XY;KQM_=R\>>WL_'\V@P\M2)57T=D
MB4B?]OIOQ;O\^1$EZ&<N2L;C2T[AR66G]<\\NSH=+Z[+U-<=$?\BZ,69;^UR
M<Z,00@@A%.^$/+Q$^_MU?VE)M15?GZC%@JTFS%Z>JFZL!V^P3V"&NKG^TX9,
M[#E8CLP+K>BT>N /3NX0.]$T_HA1*G^BQ8N-Y8;C_DBF&5,RNO1*4J)H=IY%
M._#?B8!WWA+PA$PD$IYH]D=QQNS'1]6]>.U"-Z9GW=JKLD3 SS59\([:RRFM
M7M2IO1V(3IR E\_I=OI1T^A QOD6[#M>C8V?%>'5]_.T0)^^,/DWXGPLUO2%
M)S%W11JV?%F,^E87-PHAA!!"\4[(PX?H4W'<1;A?J>O&9_^IQ.(/\C%[V6E]
MPSS4(1/G["4EX+?N*\&9T@X=0!4**^$P"2WXP5+Y)G<$/S<;POW%?"MF9IN1
M=)L8DB5B?J[)BI4E1@G]58=10A]A"?W$[D4E7B5OP>X*P&KWQ;U$3+K<03T=
MX7X<:2C;+!1SW/,M 7Q<VXN7"FWX[YP[]^K4S"XMZ%\LL&*5VJ^RMUO<87@F
M(,0N&([J:T51I04'4ZYAP]X+>&53-IY>E:Y=<RF)'^JLC\5Z='&R^IP<?'+D
MJ@ZV(X000@C%.R$/'1(TU><)Z9OQ?<>J\<:.?#RU//6.OM1; OX$9BQ,QLOO
M9&/'@5*DGVN&U>&#/Q"9=,<F8NB:*XQ?6HQ2>2W<LWXKA(:*(BFA7Z,$T;\;
MW+H'WBYBD-MD8GY?87F(%$15O1W'<QOQ]8F:N-8W)VOQG\P;R+O4KH7=_3C2
M4'K<.WP1F,Q^[*EV#>NX#UTSU=_/R3,<>!'P4EWB'V<'7DK63<7MNJUFZ<X"
M/+<F75\/QD.PWW[-D0<#RW<7XM^GZW0:/2&$$$(HW@EY:-#CX&+A=#(*[HN?
MJG2I_*!P'RR7'_YFVG#@GUN;C@^^+L79\DYU4]\W:1SX0<>]S6,X[CJ<3@GW
MZ4JX)_V!&-(.O!)$LW,M.MG[2*P'WAUFB-U$( ^ 1!RFY#=AF1)J$I(8SY*^
M:@DYVW/H,BY56N#UWS^!9K*K9!R<"'<IE1?'_>5"F\YCN-M>E78/Z8-_/M]P
MX.4AE8P]](3'7L#+J#:IALB^V(H/]I?B'YOS,.O-%%TB/Y["?5"\SUDI)?,E
M.KU>JBP((8000O%.R$.#..Y28GRQPJQ+Y=_848#9RU*UBQ;?#?5)_=I7-N;@
MO2\N(?U<"VP.G[K)O_<.?#CFN!]3PEU<R>=BX713[B*&!I<(HF=,%BPOMN/?
MC6Y4QWK@R?CB4Z*[J:,7/V4WZ,"S1/JA7UR7@??5/CQ[N1,>W_TCWG4X74RX
M[ZIRX>_GNO4$A*0X]ZIVX-7KGS%9]4.J'V]Z=#!C8(Q3Z%LM'IUSL>N;,KRT
M(0M/+#T]KH)]Z+5&'M#(V$JI$)+V"$(((810O!/RP#/HN/>X KC6Y-!CF$0H
MB7"7D4V)N&CRVIF+4W2PW8?JIKZ@+-8#'XK>DUG,<FSB.K9X(GJ.^UNE1JF\
ME,,G(H:TJZG6K!PSUI32@:=X'Q\".IPN@GPEW#^I-5+E)8PNT;TZ^,#IV3-6
MK"VQ([G5BT9W6%>?C':[AF(][OEEG=BVKP1_?3<WX>O$:)=\WI\V9.'[M.MH
M:'/I3 1"""&$4+P3\L S..+I4I4%'W]_5?>XBXLV8X0)T7(3+Z6S,LYITV=%
MVITS=WMU"?1$RESYK) 20W6N$(XV&8Z[]*\GXK@/)XADKO:;13W:@:]T!N$(
M]8,A]!3OHWW(I+:J$4XG/>Y5+OSU[/#A=(DL$?[/*P&_KM2.'VYZT*P$O"_2
M/ZH /RE1/W>E4[O>,OKMB26G1USZ+N/@I"5'?E\S%AJ5.\,M^?OIL=?*S\A_
MF_]NCJ[ND0<),EN>$$(((13OA#S02*E\M\NO4^6__J46\S?EZ)G*?]3?'N^2
M,7)S5Z5A]\%RY%YJ1YM9YL!'T#\!2E<^P:-NZ!O=$=WWN[[,<-RGC$((W;Y$
M5*V5,7)*P%?$4NC#%/ 4[R/$'XK"Y@[A3*L;'U_IP=]-79A^J@U34EI'O6:<
M:L?3Z1U8?\&*4PV]N-$30" <33B+0DY;$<E2G2-Y&(MWY.LY["-YN"=)\5*=
M,V]=IK[FO+;5I"=:2.#=T"6SW!=N.Z,=?GE8('/>Q75?_;_G4%1IUI4 ?'A&
M""&$4+P3\L B][IR(RZ]HC+'_9,C%7CSPP(]DWG&PI-CUI<Z<[&DT&?AO2^*
MD5/2CG9QX)50&<]*<WEOF8TM?;[BN&^\G'B/>SP.O(R16WJI1PEX#ZXX# =>
MW%/J"(KW1+'VA5#2[,*_SG=B_HE&S/KA!J9^=QU)A^M&O>1]9GQ_'?..-6!]
M1C-^J>R&PQ-"*))89H.,C[2[_,@K;M/A@2*^$VVI$=$N#P>E1W[)SD)LWU>J
M\S4.GZ[3TP12"YOO6*<+FO%CQ@U\?K12!Q#*2,IM^TOT X3KS<X)>1A(""&$
M4+P30NX94BHO-^)2*K__> U>WV+"4RM2Q\1QOV.,W*)DS-N8@YW'KR&CNAOM
M2JCX(@/C(G+E/>6]ZWK#.-'JQ=LRQ[W IF>VCY5POSW9>W:>13OP,D9.YL#;
M@U%$J"4HWA.DP^Y';J45[QV[AED?%2-I5]&8K\?5^[[RU65\;6J&S170X92)
M((G]%3>Z<>!$K7:_$[D.2+F[3*,0EWW=Q^>Q]T@%CF;6(Z>H#<7J&E3=:$=C
M>R_:+9X[5IO%K45Z<;4%A>6=R%8_DW.I70=K,F6>$$((H7@GY,$6[N*@]090
M?LVF9S,O_N ,9B\?>8_['RXEWJ>IF_;'UN?@3_NO8HNI#7EM'C1[(I"P]K'L
M5#5*Y0?0J!UWC^YQ?R'?.N+ KWB6C)&;:[)@17&/+J&_; _"&>JG@*=X3PBS
MW8?SE1;L^:$2+[YOPJ.K,S!M61JFCL&:MCP-,U:FX]F-N5CVR47\F-.HSW\I
M-X\7<;>MZCN*.[[A7Q?U@[Y$K@-SU.O_]GXN]APL1TK^350WV/7[2;]ZGR>D
M?S^2B2$/%(9;DLDAKY-*(4>?L7K5G]GK3@@AA%"\$_+ (HGOO>X0+EPUX\N?
MJ['H@WQCCOO"<4J*7I",J>NR,6W714P_= U_3F_'MLL.I+;[8/:KF_+HV*G<
MD#JV&E<(QUH,QUV$^\PL\[B(]MO75%U";\&JDAX<^M6![V?Y/,5[W+B](31W
M]NEY]EN^*M:]W6/U,$W:8$1L+]]5B$.GKJ&LUJ9=]'BG/TBX74 )Z/H6)_[G
MT&7=;_[HXI2$JF^6[BK @9.UR"_MT,=Y/XWN(X000BC>"2$3RJ_CX)Q&.)WT
MF2[89I3*B] 9ZW)YO1:?PM25&4C:782D;VN1]$LS'I7Q528KME<X83+[T>2.
M:-$]&@TO/^K6X^ ,QWU#N1%.-SVK:]P<]^%ZX)_*$P%OQW<W/;AB#Z(WQ#%R
M%._Q(>>FA#G6MSIQNK 9F[\LQKSUF;K4?*3GYK18:.33J]*P=&<A]AVO04VC
M0[O7(MSCW9GBNO>X_#A_M4N'Q$G?>KR][O+]GUV3KJXW%:AK=L"FKC\A=:[V
M\[P@A!!"*-X)(<,CJ?*!8%3WB<J()TEVEN"H<2F5'UQO9>M>VRG?U&+*B19,
M2>W08EKZS_]<:--!<N+ 6P-1'3 W4B)*"-0Z0X9P+S/"Z2;"<1]^C)P5RXKM
M.-C@1J4C!$<PRLU'\1[W0RCYGDV=?3A5T(3M^TNT@)=^\9'.0I>'<Q)$>?CT
M=5RYWJU+S27O(J'S2YV;-UJ<^#FG :]O-27T,$%<^HVQ<9$>'\O<"2&$$(IW
M0LCO"X*8X][M\*/RAEV7RK^Z.4^7RLN\Y'%QW-^(.>X[+V+*027<CS=C2OIM
M06\R?SK;C*=,%NRH<"&ORZ=[X /1Q!SX0<==W/N?F[UXJ]2N'7<1T4D3+-QO
ME=";\42N!:M+[#C<Z*8#3_&>\/GJ#T;0T.;"Z<(FO/MYD1; B8YDD]>+<%^V
MJQ!?':M6YWX/^KPA_1 OT1GOXI0759AU/L9?WLF.ZYHASKS\#B25_J?L>CU>
M3CZ79P$AA!!"\4X(^1W$99,@J$N5%GQT^ H6;L_'$TM/JQOK<7+<I9QV;3:2
M]HCC7H,IR:W:<;\CJ3T6]O92@57/8$_OD![XB';@X[G!E]>(B2>I\C_>-!SW
M.7F6>^*X_UX)_>*+1@^\X<"S!Y[B/3[D89LW=MPR*DT<>"D]?R1.!U[$]9P5
M:7HVNHQ@TZ7R?<&8<$_\^TB_>\;Y%OT@X;FU&7&FRR=CUI)3^KO+YSO5YQ-"
M""&$XIT0\@<BP.;PH[S6AGW'JC'_W5Q=*I_(;.;$>MQ3,'5UIN&X'[IF..YW
M$;K3E=B>8[+BPTH7,CM]:/$8 OZ/9C</ILHW]$5P3#ON1H_[O1;M0]>L'#/6
MR!@Y[<"'= I]F%7#%._Q'GL@C)OMO;J$7DK/7WH[ZZ[!DN*XRSF^?+?AN$N^
MA22U1T=1^>%5W^/[M.MX;4N>?N]X_OU%N+_\=C;V'Z_6R?:1*!]=$4(((13O
MA)!AD=Y2Z6\MKK+BG]]=P:+M9_#XTO$:!Z<$A;SOFBPD[;F$I#]PW(=SX&64
MV[P"*S:6.Y'5Z4>;=U# #_- 0LJ*E7"O[[OEN#]CLDX*QWTX!UZJ =XLZM%S
MX*6$WJ$$O.@82AF*][LA@EN$=T/[+0=>PN=$H$\;)IQ.>N.?7I6.!5M-.)A<
MBVM-3NUXZW"Z$6XX*75W>8(Z)T.$>[Q3*9Y9G8ZW/KZ Y#,WX?5'1OSYA!!"
M"*%X)^2!)AI+E2^JL&CW[;4M)LQ>GCI^CONB%"1).-WO]+C'(^#%@7_AC!4[
M*EU(:_>A50EX7^2WI>;R_[U*N-?&QL%)N;W1XS[YA/OMQ_9DGM$#+R%VEQU!
MV$-1SH&G>(\;]V"(7;[TP%_"R^]DZ_%O0QUW.<=7[CF+;T[6&N/@M.,^NE*/
M0#""#JL''QXHC;ML7P?5K<_$[H/E*"CKT&7WA!!""*%X)X0,01SW'E< I=56
M[#UR53ONLY>-4X^[/ Q8)*7R6;K'73ONL53YA$5N9A=F9IOQ8H$5[UUQ(+M+
MQLB%8R%V [>5RAN.^]M*N#^OQ+ZX]DF35+@/=>"7%??H$+O+XL 'HRRAIWB/
M^V&<3(J0$+NTL\W8MJ\$+ZS-P&.+4[2@EFJ:9U>GXXT=!3APHA8W6ER&XQX=
M&+7C+>]3TVC'YB\O)23>YV_*P;[CU2BKM>K .T(((810O!-"AMSDR\WVN2M=
M^/QHI0ZLDE3YD8Z:NNM2HB%IG8R#N\UQ3^L<55*[./ O%=JPY:H3*6U>=/HB
M\$;Z]2SX&F=8I\IO*+-KEWY&UN06[4,%_%R3!2M+[/BVWBBAMRM!QA!ZBO=X
M$0>^M<L8([=M7[%VX&6.^IP5J5BQYZP.IRN_9M-A=XF.@_L])#.CM,:*39\5
M)23>_[$Y#T>SZE'7[.1X.$(((83BG1 RB/2E1M7-NMQH2[GLIS]68L&@<%<"
M>]S&P4DXW>XB)'U;@RF_C$ZXWUYF_FBV&<_E6['UJ@O973Y4.4-HC#GN4BK_
M@OJ[Z5E=D]YQOR-=/].L4^A%P$N(7;D2\!)B%Z*"IWB/ PF@#(8,!S[]?(MV
MX.4\7_O/\]IQKY54>??H>MR'TF[QP%32@76?7-!SX^/]]U^T/1^9YUO1IGZ>
M876$$$((Q3LA)(:4QXK(.7^E"WN/5.AQ<+.7QQ\N-:*U+D<+=^VXC[!4_FX]
M\.+ BUC_I+97]XNO4:+WF3-675X_Y3X2[L,Y\$LN]>!;=4Q7G88#3RC>XT6.
MI<WL1M:%-AQ)OZ%%<E6#70=4CK50KFMR:@=]Z:["A#(SENPLT!5 TL+3SX=3
MA!!"",4[(0\[AN,^ *O=I\ME_^^G*OQCLTD[[H^,5ZF\..ZK8H[[K^%TG>/B
M5,_*L6!>@4V/6]M9Y<+\LS8M?I/N4^%^JSV@"T_F&B%VA^C 4[PGB(Q1% >^
MM<NMQ757MU<?7R0Z,.:I[E=O=&M7?^'V,PF)=RGCOUQGT]^+2?-D0OE_
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MV"+Y.;I0?MI3*)MVY<NZJ%P]>"\U?; ^*D]_YE[\[HZ$$MF?<5Y3E_B\,^8
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MCJQE?LYX,^Z,?USJ.7.&*I>3YO/8"WA6]MG^:@2\F!^\MS[][JB\LBA1)AG
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MR0!X\N$!^V-B*X:-B=TC!L"_G%YC^L$!\(%@2)4'%KS?N> =V38@Z+U5Z0I
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MX&'@C]8X.?#M=^B+W()W42DJ+-/#+^\R8'&GI^NY]_8:D)JN<F'7: U <<2
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M3 ,BD,I_'"Z50MD37VJN<K E($ YN,\S9.0& ]QWG/<-N-\5+F/V3&*5K#'
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M06L=]QD8&47YP[ASD'M]KU/'W>=R< #%A_9=DLFI =E0W"A9->U2;T!Q: B
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M29;H) O>;;/@W3;;AE3C9=AB-N[T[$KS@C2'S+<<J9A70Z$^Y;@CE8=Q_]X
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M>-WW/W=E%'URHH 2LENHHV?0;\_.W#]"9VY5TLNK8W3_]G]]E$17$NJHL7V
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M&6"ALP]M5-[GY(BQ3!L30]## .^@8V)L/L@VT8)40U  /"X\]]7Y%CI=9V.
M1[:!,P B\ K>%;Q/!-YG+XND=W>FTJ9#V;3K:!ZGX_KCVG$DC][;E2I^3X2"
M]V>]YP+>6SJM=#.U05>Z\N/1VO#/[PA8KJ8'#0K>_^AZ29PCD %2\=!"_5;)
M\"X^NU(\BZOQ=;1LK_X2" 0_WMR:1-L/Y_KM?=U]HH V"Q!?\NEMFK\F1L&[
M,F4*WI5-=T/$?41 8E:I@?:=+A*'PQ2Q*4;S 4D*N./:G$(AAPHIY)( ]Z@V
MFA'7*0W@D"K_=H:1+@@@;K*-DFUTG-R2QQ2 :+*[Z>?&05J5;_:DRG?]:5HZ
M_LU+*=VT(M?,Z>SW+ [ISQ\,A"R$(O%=2#-?FF,*&GB'0V1.BH'>SS;2J5HQ
MG@+@>QUNO[]S"MX5O$\$WL.6:-%WU'O/7Q-+"S[TSP4 >'%%)/\>!>\*WOT*
M[[],#;R[W&XJ>-!-QZZ5L^/*E_,.GB>"(?YZ7W'A^^>$1^L*R"AX5Z;@79FR
M #6.N MP[S(.4>:]3HZX R3FK9*8*H^(^Y84+>)^47[$?7Y:-ZTMM-#9.BN5
MF+6(NUNJ=WZ<'.(+JOI'Z4;+D"9.E]Y#LY,-/@$GB]@)@/_QH8W*>IV<WBX7
MX,>I6VS0A28[1^"7YYHXC3]8()XU!?(?B=@9Q7CZ,P*OX%W!^T3@?;I>&+MW
M=B33=3'? >I/UG K>%?P/AW@/5>L63^(<]*[.NK&I_.EX%V9@G=ER@+4D"J/
MB#N$3'8?+Z WMR9R5$?JQH!4>43<+]?2C-@.Z2G3[V08Z8P =^.(BZ%:MD$4
M#>KUOS8/L0C<@N< X%D"XA$%/UQMI7(!\%-RV'2-4XG%P4Z#15G!$X'W.D7>
MSC1R"GVIQ<G/2<&[@G<%[U,#[P">B/0&ZC(-LOJU@G<%[],7WI,5O"M3IN!=
MF;*I,ZC*C[G<''%/S6^G0Y=+N2W-RZNB)=:X1S]J!X=4^9MR(^Z YK4%%KK<
M,"A@U$G#8Y(C[N+R1MR][> 0N7XAV?!<L/E:>@\MR]':R!6:--$UF3;F:2-7
M:-;:R"'E'V4'P12!1VN\8S56RC,Z^%[]$8%7\*[@_:\&[X!7[#=(F7<](<:I
MX%W!NX)W!>_*E"EX5Z;LJ>!.8@-U4^^ G=O!X<#TK^W)\B+N.(R)@PA'W ]Z
M:MRCV^6T"$LT,/#.3S6PJCP4U)MMHU)5VWE,<4@;&Z>N81>GRB-:OE! ]V3=
M%U+NP_.T&OB*/J?TU']\M%7,$;18PQ@NRC;1B\G=W$,]& !^II@CR(HX+>ZM
MV%,##^&^J41X!>\*WO\J\(ZZ> CM03T]OZ+[J6.AX%W!NX+W0(+W2/K'YD3:
M>32/DO-:?Z=1H4R9@G=ERJ80W,>XC_L(1T .7"CA \7\U;'R(NYP"GR41B'?
M%#ZJ<9<D3H?>Z:^D:>KB/S4.4IG%*2!TG%R2%6CM8YJJ/*+\6R8AXOZ[^TKJ
MHE?3-1&[4W4VRC<ZJ-_ID@J;2/_O00T\ +[6RO7B$-(+EO1Y9!.@KO]H]0#E
M(@)O=W'=OX)W!>\*WB?W HC^8[,V9^^+<5?PKN!=P7M@7PCFH+7A$3&V194]
M9'>Z2)DR!>_*E$TYN(_S8;';,LSMX Y<+.&60U"5#Y,A3@<5XO!H"MV<K*7*
M ]PC6Z6ERB.:BE1YI'F?J+%R'_>1,;E]O<%Z0ZYQ:K"-4D3K$*W.,],K K)E
M]$J'2OT\ <\KQ7><%/=WO]=!?4ZW9/$]XJ@TTO5/U&IMY)!V'A(D$?@YR09V
MB" "CU[W)H>60C\5"*_@7<%[L,([1]H%?,Y;%4T+!6#_<ULR;?L^ER['UHJQ
MLRIX5_"NX#U LV->PCLKQO^?VY+HX^,%%)O1S/O4\ZRURI0I>%>F;(*&B+ME
MP$[IA>WTY8_%M&AWJM;'79:JO-@(N,;]H"?B'H&(NQR!.L DHMW+!8C]W##(
M=>=H?2:SCSL^>61LG)H&Q^ABO8TV%%JX'=RL)*3O=TG*+.CB'NS<1LZCF@Z!
MN7&)]^@4GV^VNQC@(?P'Y\'L)$-0 #S&$\Z(I6(\C_%XVKD/_%0$X!6\*WB?
M*+SCH(U,J5FXE@7>A:@=[FGQGC1:?R"3/A=0'G.WB1K:!\CV!_-5P;N"]^D
M[UBS#E_U76T^D-]9.-H [:^MC^.]:)UX9[\\5TP1MQNI2<Q=S.'Q\7%2IDS!
MNS)E4V1/MH.#.!UZE$IO!X<^[MZ(>X0\<3J ) !L;8$FZG:_UR-.)W%,76)0
M47=>/>"DFRV#M%& ^ZMI/1S]GXJ4;S@J -&(&)=:' S74AT_8@X9/0 /I\'2
M''-0M9%[*<6@931X -XT!6WD%+PK>)\(O./P__=-";1L[VW:]GT.?7JJ,."N
MSTX7\3X#T+N6])"2<]NHL=W*]^OZ@_=*P;N"]\"']W&Z5VVDL[>J?'J6F--O
M;$B@U5_<I8]^R*4])PL"ZGW=*RZ\>P<OE8HU\8'8DQY26D$[U8CG\61+1V7*
M%+PK4S8%AH@[#OB9)5VT[TP1>XQ?\JC*A\E(E<?A"WW<#Q51R*5:+55>4HV[
M-^*^*-M(EQILU&@=9:$UU+C+]!0#W TC8W19?.<J 7V(N,],G+IH-"+&\U*T
M"/S1:BL+RVGW+,D!1)H*?9_#3<46!YVKMW&6 WY'L$3@YXKQ1%D %/8+/*K^
M,@^""MX5O$\$WN>LB**-A[+I8DP-%5<9J=,X%' 7',7=YB$R":#NM=II0("9
M QH=SUBC)@SO!P2\"S V]@8PO'<]#[Q7446]@O= @'>W6&[P&S'?EHM[\F7-
M7O-E!D>RRVK-U&$<#+QWUC3$)96F7KRS#GX>=C'GW&X5<5>FX%V9LBDS%J=S
MN:FC9Y#N%'70MS^5,22@#E%:Q'V5V'2W/M8.3J(X'2+N$!U;7VBA\_5:W^YA
MR2KLB+@C(EO9/TK7FP9I<Y&%!?)F3:(XG2\1>*^(W>E:&Y68G1P=E^H($H<7
MXXB+G06 7"C@!U,$WMM&#JK^>28[B]@Y)*D=*GA7\#XA>!?0A/N/N-/(P!LL
MYBN\(PUY_NH8"M]WAZ[$US%X!*(!NMN[;10IX/6#/>GZ!<,$O"\7]P:8+7]H
MIA&[@O= @/>F#BO%9;;0ROUW=?]&U))O_C:;[A9WLF-+9: K4Z;@79FRIQH.
MMM@0<\0A]Y/C!2Q @@U7FC@=U.HA3O=M$85<KJ49,>W2("N$Q>D,W.[K7/T@
M=0V/L3B=6W*-.]C8(OYS58#[XFP-7$,1<4\T^ 4V$?6&JCWZP/]09:727B>K
MQ,L5L1NGP5$WW;,XZ,>'5OH@VT@S@Z0&/L33L>#=+!.=K-,R&GJ=+BGCJ>!=
MP?N$X?UP+D?Q@A'>9_H [Q@+O#M(+4?D,! -&0<]EF&*SVKAN>Y+Y'V)@/UC
MOU90:8W)[^G+"MXU>&\3\S0YKXU6?Y&AX%V9,@7ORI1-'EPA51ZI4*EBDT$=
MT[]WI6@1=UGMX%9&>]K!%6BI\A(C[K.2M'9PZPLL]%.#C8%U:$PRL.(0YD+$
MW<F">%N+>UG9?G:R(2#:GKTJ?LM23U][B-B9[7)5]M%2#5'I(D\;N37Y%AZ/
MD""*P*_(,].1&BOEF.S4/3+Y-? *WA6\_P;O&WV#]ZW?Y]#UE'I.QPX60X;8
MMY?+.)H^6^=\X'=A<R(=OU;!?Q^(YG*YN4=VEGA7T>?>%^![>T<R?7&NF'+N
M&_S^GC\/O"_WP+NF6O[7A?<[Q1T*WI4I4_"N3-E_F[<=G+G?SNW@/C]33&]M
M3V;U7RG0OL33QQT1]T.%6L0]NEUJ;3(B[NC/#7&Z9MLHV5UR6WL!#Y".WS$T
M1O]I&>2ZZ(7I/0$'G"@C\-; EUD<-#0F5S4='PU]@6*SID*_6(S+G!2#E#9Y
M_K@@/HC,CE-BGJ'7O=FA]8&?K"%5\*[@'6MU?%:S>)Z)+$2GM__RAH-96MNU
M]H&@V;O@; :$8RSF^@"&J'L'],.1X0Y@*BJI-K)@F2_"A/_8G$ [C^;1[:(.
ML@WY'][+Z\QT^D8EP[@O9XKPS^]27&8SM7;9N)1O.L-[>_<@!T56?^E;VOQ&
M\<ZFB+_#WRMX5Z9,P;LR91YP)QH5,&4P#5-*;AM]?:&$WO\XC2,94B+NWC[N
MV],HY*#\&O>9G@CSVGPS76D<I/)>YV_B=+(,GPUQNII^)UULL'&-^X+4P(BX
M/ST"W\-"<E!-SS':J=<I5W0-*?K>&G@HWZ\1SP9">L&20@]-!8PG1^#%>';;
MW>*>:5( 7L&[@G?\_O2"=E:.G[\F1G<Z]=*]Z73X:CG5-/4%S?[5;1ZF\U'5
MW,(4>Y;>^;#PPUC:?[:([M>9:%"\4X$*\(!WB):%^=A58,<1 >^%@'>GW^%=
M"P@4T=L[4G@>ZGU&ZPYD4<&#'AH8=/[A\YD6\#ZNS5.LN^N^SO#)$0,'QI6$
M.JIJ[ UH)Y,R90K>E2F;JHU5; :.49< ]R'**NEB<(>J_%RN<9<4<4>J_);D
M1^ .5?EX>:GRJ"\''"+*"YB6W0X.&[5-D%J]=91NM@S1:O'=@..0  =.M#T+
MSS5Q2S>4%/0YY3HX,$YP$B Z?;+.QCW37TX-G@C\B] 4$..IM9%SL"B@<Q(B
M\ K>%;SC]V>5&FCCP6SZVZ9XW2#PUD=)W-X)P!HL!K7X7Q(?<G3ZU75QNN<#
MG!X?']/>!:C;C[D"$XR@,H[GC(BU'F<Z_LVKZ^,X8IN<VTK60?_".WJ<I^:W
MT:9OLUFC04^F"-XKW,>6;W.HNJGW#Z/NTP7>D=G89[5SEX=-A[)T_T:,P:+=
M:71$_,["RAX%[\J4*7A7IHSXP-([8.?TNB_/W^.- H>:6;)JW)=&4NC6% HY
M(,#]?!7-N-&L"=3%=DSZ%1+700L$D"[/-M+E>AM5]CEI0#*0XJ-1XXZT_$MU
M5MJ89Z+74KIH%K(*)-SC9%YA8KP6)G71BJP>.E'93X4]=G9TR!PK1*--#JT/
M/)PKX3E&FAD_A6.%YQ(OKU0#-?#0%( *?3ZWD7M^$3L%[PK>H4V2=[^;HZMO
M;DW4V2(MXK?^Y@"!\2 ! 91Z1=YNI*W?Y=#??-  @)8+ZHEC,IJII<M&SE%W
M0-Y?96,O[3U51&]L3- 5M<:<Q+_#VG KK8';=XW[]8SAIKBL%J[;7[ F5K<#
M0NN.D,=@/MWA'892EX:V?MI^.%=W8 3C\,Z.%/KRW#T.KBAV5Z9,P;LR9;RA
M=!H'Z9?$.EJ^[S:]+"M5?K&GC_ORJ$<"=2?+&>!#+E9+N4(OUM";-QMHUYT.
MRFRST:  =]G',X"9=62,2MNMM">YF=ZX5$FSSE10R*GR:7&%G:Z@UR]6T=:8
M1HI^8"+K%"@5(X6^TS9*:<T#]'%Z&\T]7TFAIR6/F7@F,RY4TXQ?&VA&5)O4
M"#S*);85]U)$ZQ"U#8T]M_-(P;N"=\!,28V)OKY8PNGBNMN("2!:NO<VMP"%
M"GDP]&*&\SDQIY4^/55(_Z?3D8$+V67HAXZ4>_1#MSM< 7E_=2W]W*Z5,^)6
MZJ\7AP; I9@:WM\QW_T!?G 0037_9EH#_7MG*LU9H2^C#\Z'US?$T^=GBZBA
M?8!<SU@TIPN\X_,A.O?YV6)V'.G-0$ )Q);O<GB.J][IRI0I>%?V%S=LK';'
M&+4:K'0YKH8/P]+A?44TA6X0!ZP=Z12Z^RZ%[LF0=LW\-)/>.UQ 7]VHHKP:
M,]D$5+M<<O$=GV\><%#>@V[:>>8>O;XKC6:+^PU;ET"AZ^(#_$J@6>*WOK8S
MC=8?SJ>;=YMI0'*]) XT3G&P[.X=H>S*'MI_I9P6[DCEWR'S/KELX[,L"CE>
M1C.N-TK5$T#9QOI""_W4.$@-ME$%[PK>)V&=&:<: 2P7HJNY'MJ7&MIW! 1&
MI#=PBS2[TS7M][$!FX/G,[JC_&M[LD\MU?#OO_BQF*.:@?H^ %Y/W7CPFW-=
M[_T!^DY<JZ"J1@O?FS_ #^\9G@]$$O%[]+;SF[LRFCO=(%V\Q6 CESLXX+W;
M,LR:$__<EJQ+=1^.#N@X+/HXC:XG/_2;$T:9,F4*WI4%D&$S0-HA#C_?_5Q&
MB_>DR6L-AXU[622%BDTS],,X"ET;+_4*$]??MJ?2VH-9=#&F1ARZS=1O<TA-
M%\4!"0>EAZW]]&OB0T[[>WU]',WV0:3'7Q>4;5]=&\>M;,[>JJ)[U48:<<B+
MO+-0HIA_J#?-K^CF ^JJ+^Z*0U6T7 <2YM\6E&[D:]%WB"5*2IL'N(?GF3EM
M/KO'3B:[Z[FS/Q2\*WC'.H-4;Z1\;_L^5W\-[1)-B?SX]0H60AOP<SWT9!C$
MYE##CPCZ!Y^D^>3(6+@VEM9\E<&1X9[>X6>F9_O+T,?^:F(=;3J4S64/>N_O
M-;'O?'7^'L]WD]CC77Z =\RONI8^.G+UOD^_'6*":[_.I)_C:CES("C@75S8
MZ\Y'5K/JOEY'#&<AK(^G$^*=A:CP\!1DPRE3IDS!N[( MD< -<P'X@,72[A'
M[$OAT;J]Y!,"*%Q+)5\L>A-)"];$T(?B@/9C1!75-/4*^!F3*OR"S\9WH 41
M>M0"2%]9%\= *D4$<!(N'&3GKXFE9>)0<>S7"E:V'9(8K<&GXJ#<)PY-90Q#
M#VB1 %&OXRAL282\S(]-R13R9:X&[M%M4FK>$7&?Q_7N9CI</4 %)ONDZ2TH
M>%?PCC6FQS),.:5=7 ^M=PS"N.X]CMN(18JUR6 >IND>R$-:-@ W-J.9T^!]
M61.P'N.=.'ZMG&J:>_F="+3()E3*DW):Z;/3A2SXIO?>%@B0_>B''+J5WL#C
M\SQS?J+6T3/(8G5[3A3XU D *?.?GBRDA.P6!EYW$, [#/H#<!1!GT&ON"+>
M690;[!7/O["BAZ/WRI0I4_"N["\/\%I=&CS<=XL[Z/"5^_3^[C0M BH+X*<T
MHAQ!;VR,IW4',CG-%(JOL@]I4-@='!:'BI8^^D]*/1^67UX=3;.7!]YXLCJQ
M.$B@)<VYR"H>'QPRD)HK8XQ8J,X%AY&=A;/0HWGE_KOL9)DE$]S%? Z!6.+7
M>30#8HDWFZ5T.0"X+TCKII6>B'NNT4X](^CU/CGCI^!=P3O>2[0 JV]#/72I
M?ECUU'HO^B2-TW?K6_NG?2HNUBGT,B\08+/AFRR?UP9$>;=]G\/B;LV=UH"K
M*T:VV/TZ,YW\SP-Z<UN2_IK^E5&\/J!>OORAF??XJ38X@4][,JKFAOM2KY_
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M 8A(%B[\*:Z6M6+@9!H=F_Y9,\J4*7A7IFP2-F"M__L0IQ&B]NR]7<$#\-@
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M*P;.[MPR R6(^P"T(SL/[RQ*<^:PR*UOO^NM[<FT]U0A0RC@4^]:JA?>_Q\
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M"'C-O8' &X9$H#JDH*94/&EEP\#L0QT*?(TZ\* Z+/PAD?ZB#L5)+E"H)R_
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MDV;-C<%GXR@N[;DPQB#6& <4@T35=XP1TBA6[D[EW/0_&UN<?2MWW^;/(VH
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MCWN(N57E#<7]EW(MQ]V$/NYOZ<7IENB*>X[>#DXBY04"@4 @$ @$0MX%@E$
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MJ?)L[L;&4KCOQ1TWP?W'HIB!.^GR]Z=5R0P#[FL-N)^^X9$F UD]%MS[C3:
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MI\3'SF&AXG2)_NW@XB_'L!U<C;R4=;,=7(/'ID@&&DX;0"6JV1[F.:.5,-D
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MWS/5/].!UG2 X!M?9LJS\U/[Q>WX&6#OA07ILBNC5"%W^=93(P+O8R=[H6W
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M;,;YVM,!2-P3$(<@'<X4QW'(OTU:L$\%[! 'PQ&'1L=(P/O$J5YX'FCN!!X
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M4A56@X]B15-NM -L'T?[RSG3*2U=$WJ'0:3VC$FJL8E).9S?JA^K0=T''SW
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M    P+P#  " >0<   #,.P   &#> 0  P+P#    YAT   #,.P   &#> 0
M /,.    YAT    P[P   (!Y!P   /,.    F'<    P[P   (!Y!P   ,P[
M    F'<   # O ,  (!Y!P   ,P[    8-X!  # O ,   #F'0   ##O
M8-X!    \PX   #F'0   ##O    @'D'   H>P   /__[-<Q#0  #,.P\2?=
MD>A3R8:0+PFTG 0   !@W@$   #S#@   .8=    ,.\   " >0<   #S#@
M )AW    ,.\   " >0<   #,.P   )AW    P+P#    YAT   #,.P   &#>
M 0  P+P#    YAT    P[P   &#> 0   /,.    YAT    P[P   (!Y!P
M /,.    F'<   # O ,  (!Y!P   ,P[    F'<   # O ,   #F'0   ,P[
M .,>  #__^W7,0T   S#L/$GW;&H>M@0\B4! &#420    #F'0   ##O
M8-X!    \PX   "8=P   ##O    @'D'    \PX   "8=P   ,"\ P  @'D'
9    *AY_Q&L@?E9#R     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
